Biometrics: November 2013

Maritime Security Market Worth $19.48 Billion by 2018

DALLAS, November 26, 2013 /PRNewswire/ --

The report "Maritime Security Market [Access Control & Biometrics (Finger, Face, Voice, Iris); Surveillance and Tracking (Underwater, Video, AIS, LRIT, Imaging); Detectors; SCADA; GIS; Communications (Satellite, Radio)] - Worldwide Market Forecasts (2013 - 2018)", defines and segments the global Maritime Security Market into various sub segments with in-depth analysis and forecast of revenues. It also identifies drivers and restraints for this market with insights into trends, opportunities, and challenges.

Browse market data tables and in-depth TOC on "Maritime Security Market"
http://www.marketsandmarkets.com/Market-Reports/maritime-security-market-1033.html

Early buyers will receive 10% customization on this report.

The major forces driving this market are awareness of Maritime Security, maritime threats, regulations and standards, and international trade by sea. The significance of the Maritime Security has increased, due to globalization. The increase in maritime threat in some regions of the world has been noted as one of the major factors affecting international trade.

Solution providers such as Kongsberg, Raytheon, Term, Thales Group, Northrop Grumman Corporation, and many others are expected to provide integrated solutions and offer better competitive services. The companies in this industry must take advantage of the growing awareness of Maritime Security in the new markets such as Middle East and Africa (MEA) as well as Asia Pacific (APAC). The surveillance and tracking systems and solutions, smart container systems as well as scanning and screening systems have a high growth rate in the market.

MarketsandMarkets has segmented the Maritime Security Market by type of technologies and systems: screening and scanning, access control, detectors, Geographic Information System (GIS), surveillance and tracking, weather monitoring, smart containers, Supervisory Control and Data Acquisition (SCADA), communication, and others; by type of services: training, risk assessment and investigation, maintenance and support, consulting, and others; by categories: port and critical infrastructure security, vessel security, and coastal surveillance; and by regions: North America (NA), Asia Pacific (APAC), Europe (EU), Middle East and Africa (MEA) and Latin America (LA).

The Maritime Security Market is estimated to grow from $12.55 billion in 2013 to $19.48 billion in 2018. This represents a Compound Annual Growth Rate (CAGR) of 9.2% from 2013 to 2018. The vessel security segment continues to be the largest contributor for Maritime Security. In terms of regions, North America is expected to be the biggest market in terms of revenue contribution in 2013, whereas APAC is expected to experience increased market traction, in due course.

Browse Related Reports

Critical Infrastructure Protection (CIP) Market [Network Security, Physical Security, CIP Radars, CBRNE Detection; Vehicle Identification, Secure Communication; SCADA Security, Building Management]: Global Advancements, Market Forecasts & Analysis (2013 - 2018)

http://www.marketsandmarkets.com/Market-Reports/critical-infrastructure-protection-cip-market-988.html

Physical Security Market By Products (Video surveillance, Access Control, Biometrics, Intrusion Detection, Security Systems), Services (Remote Management, Technical Support, Security Consulting) Worldwide Market Forecasts and Analysis (2013 - 2018)

http://www.marketsandmarkets.com/Market-Reports/physical-security-market-1014.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductors and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
E-mail: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/market-reports/telecom-it
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets

reade more...

Can (and Should) Retail/Wi-Fi Analytics Help Retailers Survive in the Age of Amazon?

MOUNTAIN VIEW, Calif., Nov. 26, 2013 /PRNewswire/ --

11:00 a.m. EST on Wed., Dec. 4, 2013

Complimentary online registration

Stratecast | Frost & Sullivan Big Data and Analytics Global Program Director Jeff Cotrupe

The retail industry is enormous. Yet this massive industry is facing sizable challenges. For starters, the global economy continues to struggle because consumers, generally, have less discretionary income and are saving more. The "Age of E-tailing," or to express the concept in its leading brand-specific form, "The Age of Amazon," is placing a vast multitude of items that at one time were available only in retail stores at the fingertips of consumers, on any Web-enabled device, at lower prices and with minimal wait times to receive the merchandise. If retailers are to survive, they must find ways to engage with shoppers, or, at minimum, to better understand what shoppers want.

This Stratecast | Frost & Sullivan Analyst Briefing introduces an approach that is helping retailers better understand both their customers and their own operations by harvesting analytics from the Wi-Fi that many of them are already providing to shoppers.

Designed to benefit a wide range of attendees, including:

All retail or e-tail organizations, and individual retailers of all types and sizes Every brand that sells through either the retail or e-tail channels Brands that utilize mobile technologies for sales and retention activities Companies that play a role, or could, in equipping retailers to better compete "Retail/Wi-Fi analytics is one of the most compelling examples of a direct, practical use of Big Data today, in a realm that potentially touches virtually every consumer," said Stratecast | Frost & Sullivan Big Data and Analytics Global Program Director Jeff Cotrupe. "Collecting data about shoppers and their actions, both in-store and in other areas of their lives, does, however, raise privacy issues. Stratecast believes the actions of watchdog groups and key providers in this industry to help shoppers opt out are moving the state of the art in this space to a more consumer-friendly place. We are also advising retailers to turn a negative into a positive by turning shoppers on to special deals and premium content in exchange for keeping their Wi-Fi turned on and allowing this data collection to occur."

Registration

To register for this complimentary analyst briefing, email britni.myers@frost.com your full name, job title, company name, company telephone number, company email address and Web site, city, state and country. Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.Supporting Resources

For more information about Stratecast | Frost & Sullivan, please visit: http://www.stratecast.frost.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation. The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Contact:
Britni Myers
Frost & Sullivan
+1.210.477.8481
britni.myers@frost.com

SOURCE Frost & Sullivan

Turmeric Curcumin Capsules by Everpure are Now Discounted on Amazon

Turmeric Curcumin Capsules by Everpure are Now Discounted on Amazon. (PRNewsFoto/Everpure)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";NEW YORK, Nov. 27, 2013 /PRNewswire-iReach/ -- Everpure, a company dedicated to improving the health of people around the world, recently announced its decision to offer a 20-percent discount on its Turmeric Curcumin capsules. To apply the limited-time holiday discount, customers only need to enter the code "AWSOME20" at checkout.

(Photo: http://photos.prnewswire.com/prnh/20131127/MN24825)

Each bottle of Everpure's Curcumin C3(R) Mega Complex contains 120 pure vegetarian capsules. The product has no gluten, milk, peanuts, shellfish, or soy in addition to containing no additives, preservatives, or fillers. The capsules are enhanced with patented Bioperine to ensure bio-availability and absorption.

According to a guide published by the University of Maryland, umm.edu/health/medical/altmed/herb/turmeric, Turmeric Curcumin is one of the oldest anti-inflammatory agents in natural medicine. Turmeric Curcumin is derived from the stems of the plant Curcuma longa, a member of the ginger family. For centuries, Chinese and Indian doctors have used Turmeric Curcumin to treat a variety of conditions such as flatulence, jaundice, menstrual difficulties, inflammation, rheumatoid arthritis, joint pain, Alzheimer's, and killing cancer cells.

There are several Turmeric Reviews available on the company's Amazon webpage, Many customers who have used Everpure's Turmeric Curcumin capsules as a Natural Anti-Inflammatory have reported positive results.

"I have been heavily into fitness for the last 15 years and it has been wreaking havoc on my joints because it causes inflammation in my joints," said Dmitry Godzin in his review of the product. "Turmeric Curcumin provides spectacular inflammation relief: a few weeks ago I hit a New York State record in powerlifting and my joints feel great. Everpure's Turmeric Capsules let me train more days and with heavier weights so I was able to reach my goal."

Individuals interested in learning more about Everpure and its promotion can visit the company's Amazon storefront for more information. All of the company's products are manufactured in the USA using all natural ingredients.

About Everpure:

Everpure is a company started by holistic nutritionists, personal trainers and health crusaders in order to improve the lives of their clients and the people in their world. The company's goal is to help as many people as possible become pain free and vibrantly healthy. Everpure has been in the health business for the last 10 years in many different ways, including personal training, martial arts, holistic nutrition, seminars and mentorship programs. For more information, please visit http://www.amazon.com/gp/product/B00EBG2FT8

Media Contact: Thor Y, Everpure, 16468205071, everpurelabs@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Everpure

reade more...

Buy PureAand Top Quality Qlpaca Blankets Online (wist onannd)

Alpacas are a domesticated South American camelid which are breed for its fine quality fleece that is converted into many types of garments that offer warmth and great comfort in winter. Peru is one country that has been offering top qualify fiber of alpaca to the manufacturing units where designing, manufacturing and marketing shall be done. In case you are looking for some fine quality alpaca blankets it is very important that you find the right source to purchase these garments which are naturally hypoallergenic as there is no lanolin and can be used for feather weight clothing that provides excellent insulation from cold.

This is the reason you find so many products like alpaca throws, sweaters, blankets, vests, gloves, scarves and many more in rich color and superior quality. Alpaca garments are available in 22 natural colors and quality depends on the grade of fiber that comes from the alpacas. Generally baby alpaca products are very fine and smooth that are graded as superior quality and you can check out beautifully designed baby alpaca blankets in different styles with embroider borders that make a prefect give for the young children.

However baby alpaca fibers may not always be taken from the baby alpacas as specially reared adults too offer the same quality or even more. You also needn't worry about using these products as alpacas are taken care while shredding process and they indeed feel more comfortable after their yearly sheer cut of fabric coat. The material is very much durable even more than the cashmere wool and shall stay in the same condition for years to come if proper care and attention is paid in the washing process.

You can check out online for the alpaca throws designed in various color combinations and styles that are surely very appealing and match with the other garments to move around in winter without worrying about the climate. The tan chevron, beige/black, tan chex, ivory plaid, journey alpaca throws in different shades are really a treat to watch which one cannot stop buying.

As the online sites offer 100% guarantee and return policy on their products they are indeed a reliable source for buying either the alpaca blankets or throws. You can go through the customer reviews and information they offer in taking care about the alpaca garments for lasting long. The alpaca throws or blankets can also be sent as a gift to near and dear ones as they are highly appreciated for its finesse and quality by anyone.

Alpaca wool offers more warmth than any other fiber compared, which is also light-weighted and comfortable to wear. PurelyAlpaca offers natural alpaca clothing fashions including socks, alpaca vest, throws, blankets at afforadable prices. For more details please visit us in online.

reade more...

Advice on being fashionable as an traditional Greek bride (customgreekthread)

Are you tying the wedding knot recently? If you are happy with your Greek bloodline and want to dress up just like an authentic Greek bride, you need to be systematic. Right from the option of Greek apparel for wedding to wedding make-up, everything has to be ideal. You could always check out these simple suggestions for help.

* Pre-schedule your tan
Brides often like to get a tanned look before wedding. This is more prevalent among Greek brides because the warm welcoming ambience of Greece is ideal for getting natural color. Now professional advice here is that you should not get burnt while getting tanned. Wear a sunscreen cream with high sun security factor so that your skin does not burn at the time of tanning. At the time of tanning session you need to wear dresses that have adjustable straps. Ensure that the straps could be pulled up and down for uniform tan. This tip will help you in wearing off-shoulder marriage event gown and flaunting your tanning body gorgeously on the D-day.

* Pick clothes for the event
Since you are a Greek, you'll likely know that Greek weddings get organized in the evening. And hence, the selection of your wedding attire should be made keeping this thing in mind. You will also like to know that wedding robes are no longer white in color only. You can choose custom Greek apparel for the marriage ceremony which comes in shades of ecru, ivory and soft pink. A suggestion here is that most Greek women have a warm skin tone So, the color of wedding gown must harmonize with this authentic Greek skin tone. If you have a warm skin color too, a milky white bridal dress may not an ideal choice for you. It's going to make you appear dull! Thus, you must try out several other colors.

* Makeup for the D-day
The characteristic function of Greek wedding makeup is plum lips and accentuated eyes. But there should be minimal makeup in the rest portion of face. Attempt to be close to your usual looks. Always use waterproof foundation all over your face and neck for a gentle finish. Never forget to apply lose face powder over it for a ideal finish. Your eye make-up is supposed to be louder. Therefore, choose bright eye makeup products. Always bear in mind to use eye primer to make it stay longer. Use red based bright lip color for accentuating your lips.

Processing ...

reade more...

A Summary of Reviews On The Inked Shop (Tiana K. Emerson)

If you are interested in a product from the Inked shop, reading reviews is quite important. The good thing about reviews is that you are going to get first hand information from past client of the shop. One notable thing about the products available at this shop is that they do not cost much. Reasonable rates are going to be charged and even if some may be a little expensive, they are worth the value. In other words, the price will bung the bucks since it is relative to the value one will gain for buying the product.

Discounts are up for grabs and no hidden cost will be charged. The products are showcased at the website of shop and it will be possible to order at the comfort of your couch. Also, the payment can be settled using an online facility and your product will be delivered to you within no time. The other good thing is that the shop stocks unique commodities that cannot be easily found elsewhere. The inked clothing as well as accessories at the shop is not readily available in discount departmental stores or the malls.

The designers of stuffs at the inked shop are mainly tattoo collectors as well as enthusiasts. Their inspiration comes from Goth, Punk, Biker, hipster and Rock ability sub-cultures. They are also inspired by tattoo as well as tattoo arts such as tattoo brand clothing. If you have a new brand that is cool, you should not hesitate to contact the shop and rest assured you will make money out of it. The shop is the home of such iconic brands as Ink Addict, Steadfast, Sullen, Black market Art, Rock Love, Baby Rab and Sour Pass.

You can buy inked magazine to get a glimpse of what is available at the shop. The magazine has stunning photography and avant-grade content that will leave you buffed on what the world of tattoo clothing and accessories is all about. The latest fashion is going to be elaborated and you are going to know what is new in the world of music, pop and art cultures. The Inked store is also available and you will be able to shop using your mobile phone and other technologically advanced devices. Other platforms include Freshly Inked and Inked Girls and have a lot to offer.

You can get in touch with inked shop using an online contact form. All you have to do is to indicate your name, email, telephone and a comment that states details of your inquiries then submit it. The good thing is that a quick response will be provided. Some products that are available at the shop include various shoes such as boots, wedges, heels, flats and many more. You will also get accessories such bags, belts and more. Jewelries are also available like bracelets, rings, watches and earrings. Beauty and health stuffs are also available and will include makeup and tattoo care. The other outstanding thing about the shop is that the cool stuffs are available for men, ladies and kids. More information concerning the shop can be availed by surfing through the Internet.

Tiana Emerson is the author of this article on Inked Shop. Find more information, about Products here

reade more...

Turmeric Curcumin capsules by Everpure are now discounted at Amazon

Turmeric Curcumin capsules by Everpure are now discounted at Amazon. (PRNewsFoto/Everpure)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE= ';)NEW YORK, November 27, 2013 /PRNewswire-iReach /-Everpure, a company dedicated to improving the health of people around the world, recently announced its decision to offer a 20% discount on your turmeric Curcumin capsules. To apply the limited time holiday discount, customers only need to enter the code "AWSOME20" in the box.

(Photo: http://photos.prnewswire.com/prnh/20131127/MN24825)

Each bottle of Everpure Curcumin C3 r Mega complex pure vegetarian contains 120 capsules. Product has no gluten, milk, peanuts, seafood or tofu also contains additives, preservatives or fillers. The capsules are enhanced with patented Bioperine to ensure absorption and bioavailability.

According to a guide published by the University of Maryland, um.edu/health/medical/altmed/herb/turmeric, turmeric Curcumin is one of the older anti-inflammatory agents in natural medicine. Turmeric Curcumin is derived from the stems of the plant Curcuma longa, a member of the ginger family. For centuries, Chinese and Indian doctors have used turmeric Curcumin to treat a variety of conditions such as flatulence, jaundice, menstrual problems, inflammation, rheumatoid arthritis, pain, common Alzheimer's disease and kill cancer cells.

There are several turmeric reviews available at Amazon's Web page of the company, many customers who have used Everpure capsules as a Natural anti-inflammatory turmeric Curcumin have reported positive results.

"I've been heavily into fitness for 15 years and has been wreaking havoc on my joints because it causes inflammation in the joints," said Dmitry Godzin in his review of the product. "Turmeric Curcumin provides spectacular relief inflammation: a few weeks ago I gave you a record of the State of New York in weightlifting and my joints feel great." Everpure turmeric capsules let me train more days and with heavier weights, so I was able to reach my goal. "

Those interested in learning more about Everpure and promotion can visit the company Amazon store for more information. All the company's products are manufactured in the United States using all natural ingredients.

About: Everpure

Everpure is a company started by nutritionists, holistic, personal and cross trainers of health in order to improve the lives of its customers and the people in his world. The company aims to help as many people as possible be vibrant healthy and pain-free. Everpure has been 10 years in the business of health in many different ways, including personal training, martial arts, nutrition, holistic, seminars and mentoring programs. For more information, please visit http://www.amazon.com/gp/product/B00EBG2FT8

Press contact: And Thor, Everpure, 16468205071, everpurelabs@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

Everpure FOUNTAIN

reade more...

Can (and Should) Retail/Wi-Fi Analytics Help Retailers Survive in the Age of Amazon?

MOUNTAIN VIEW, Calif., Nov. 26, 2013 /PRNewswire/ --

11:00 a.m. EST on Wed., Dec. 4, 2013

Complimentary online registration

Stratecast | Frost & Sullivan Big Data and Analytics Global Program Director Jeff Cotrupe

Designed to benefit a wide range of attendees, including:

Registration

For more information about Stratecast | Frost & Sullivan, please visit: http://www.stratecast.frost.com

About Frost & Sullivan

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Contact:
Britni Myers
Frost & Sullivan
+1.210.477.8481
britni.myers@frost.com

SOURCE Frost & Sullivan

Youth group advocates biotechnology

Members of the University of the Philippines League of Agricultural Biotechnology Students (UPLABS), call their group the “emerging bastion of excellence” in advocating science-based knowledge.

UPLABS, based at the University of the Philippines Los Baños, is a three-year-old academic organization especially for BS Agricultural Biotechnology students and has come forward as an advocate of biotechnology to advance Philippine agriculture.

In the aftermath of the Golden Rice field trial at Camarines Sur getting vandalized a few months ago, UPLABS issued a statement condemning “the uncivilized act done by a militant group in an experimental station.” Their statement acknowledged the freedom of each individual and organization to express opinions and views on certain issues that affect them, but that “despite the difference in views regarding genetically modified (GM) crops, respect for each other must be upheld at all times.”

UPLABS also stated that once Golden Rice is approved by government regulators, they believe that it will help get rice enriched with beta carotene within reach of people and thus help address vitamin A deficiency in the country.

UPLABS had also expressed support for the Bt Talong (eggplant) project and other biotechnology research projects conducting multilocation field trials. In a statement following the court ruling on the Bt Talong case, UPLABS expressed its disapproval, saying that the completed field trials in various parts of the country “were responsibly undertaken by the researchers involved in the project, and were meticulously policed by the Institutional Biosafety Committee and representatives from the Department of Agriculture-Bureau of Plant Industry.”

UPLABS is grateful for the support of professors, advisers, university officials, and researchers for the group to continue disseminating factual information to the Filipino people, especially to the youth, who deserve to know how GM and other forms of biotechnology can benefit them.

In line with National Biotechnology Week (NBW), which is celebrated on25-29 November 2013, UPLABS prepared a series of activities seeking to share knowledge on advances in modern biotechnology and to promote agricultural biotechnology products. This year, the activities have the theme, “Toward the Enhancement of Food and Feed Quality through Agricultural Biotechnology.”

The week-long celebration started with the opening of the UPLABS exhibit at the Crop Science Cluster lobby at UP Los Baños. V. Bruce J. Tolentino, IRRI deputy director general for communication and partnerships, and Antonio Laurena, UPLABS senior adviser, were on hand to give inspiration and pledge support.

Dr. Tolentino bid some 160 students from the Los Baños National High School to keep their minds open about biotechnology and to share what they learn from their NBW experience to their peers and families back home.

Jayvee Rosal, UPLABS president, said that their organization considers sharing knowledge about agricultural biotechnology to young people very important, as it is a good chance to educate and influence the country’s future leaders. He also encouraged the members to join the advocacy “Para sa bioteknolohiya, para sa bayan” (for biotechnology, for country).

Other activities lined up by UPLABS for the NBW include a career orientation, a quiz contest, and a symposium titled Enhancement of food nutritional value through agricultural biotechnology with the speaker being Gerard Barry, Golden Rice Network Coordinator at IRRI.

More information about UPLABS and their activities for NBW can be found on Facebook.
(LINK https://www.facebook.com/uplabs)

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Climate experts meet with Philippine partners

Members of the Philippine Climate Change Adaptation Project (PhilCCAP), led by Wilbur Dee from the Department of Environment and Natural Resources, visited IRRI on 18 November 2013.

"The main crops covered by the project are rice and corn, and we learn a lot about rice technologies during the discussions we had here," said Norman Cajucom, acting senior vice president of the Philippine Crop Insurance Corporation and a member of the PhilCCAP team.

Roland Buresh, IRRI soil scientist and a member of PhilCCAP, and his team are developing decision-support system tools that aim to enhance the Rice Crop Manager, an IRRI-developed tool, by providing rice as well as corn farmers information on crop management practices adapted to a changing climate. The tools are developed and tested at PhilCCAP pilot sites in Cagayan and Iloilo provinces in the Philippines.

"IRRI is important to us because there is a lot of research that we can benefit from. IRRI is looking at, for example, the water requirements of rice and how this specifically affects the crop," Dr. Cajucom explained.

Dr. Cajucom said that PhilCCAP and the Department of Agriculture-Philippine Rice Research Institute (DA-PhilRice) are currently working on a way to determine the water requirement of a rice variety at a specific stage of growth. "In the future, we can link with IRRI for that kind of information," he said.

IRRI experts Julian Lapitan, head of partnerships; Reiner Wassmann, climate change coordinator; Joel Janiya, senior associate scientist; and Dr. Buresh gave presentations to brief the PhilCCAP group.

The visit included stops at o the Ecological Intensification Platform, the Long-Term Continuous Cropping Experiment, and the International Rice Genebank.

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Maritime Security Market Worth $19.48 Billion by 2018

Browse market data tables and in-depth TOC on "Maritime Security Market"
http://www.marketsandmarkets.com/Market-Reports/maritime-security-market-1033.html

Early buyers will receive 10% customization on this report.

Browse Related Reports

http://www.marketsandmarkets.com/Market-Reports/critical-infrastructure-protection-cip-market-988.html

http://www.marketsandmarkets.com/Market-Reports/physical-security-market-1014.html

About MarketsandMarkets

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

reade more...

IRRI congratulates World Robot Olympiad second-placers

IRRI wishes to congratulate the members of the Philippine Robotics Olympiad—King Olgadao, Anne Jazpher Raz, and Rey Allen Infante—that represented the country in the 2013 World Robotics Olympiad (WRO) held in November 2013 at Jakarta, Indonesia. The Philippine team won the silver medal.

The winning group, together with some of their schoolmates from Dr. Yangas Colleges, Inc. (DYCI) in Bocaue, Bulacan, visited IRRI on 12 November, inspired by how IRRI has been developing and using tools for precision rice farming. They were accompanied by their coaches and supervising officer.

The students did a demonstration of their robots, request staff of IRRI’s External Relations office and some IRRI scientists to review and feedback on their creations.

Roger Carlo Pineda, DYCI supervising officer, said that the students have used many of IRRI’s online information for their project and were thrilled to finally get to visit the Institute.

“It is very encouraging to see high school students interested in technologies that would help rice farmers,” said Corinta Guerta, IRRI’s director of external relations.

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Indian agriculture officials come to IRRI for discovery visit

Senior officials from India’s Ministry of Agriculture are at IRRI for a two-day (25-26 November 2013) series of awareness and consultation meetings on the Institute’s work and its collaborative projects with the country.

The agriculture officials, who represent various Indian states, learned particularly about the Stress-Tolerant Rice for Africa and South Asia (STRASA) Project that is coordinated by IRRI in South Asia.

The group toured the International Rice Genebank and other facilities and met with various groups and discussed IRRI's research on stress-tolerant rice varieties and their dissemination in India, developing and spreading good management practices, the crop manager for mobile phones, and several other aspects of the long-standing collaboration between India and the Institute.

The officials on this trip are Sanjay Lohiya, joint secretary for crops and director of the National Food Security Mission of the Ministry of Agriculture; Debasish Panda and Subrata Biswas, principal secretaries of agriculture for the governments of Uttar Pradesh and West Bengal, respectively; and P.R. Kridutta, director of agriculture for the Government of Chhattisgarh.

Their visit was arranged under the STRASA Project.

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Myanmar: IRRI represented in rural development strategy setting

“Poverty reduction in Myanmar is dependent on the development of the agriculture and livestock sectors,” said Myanmar President U Thein Sein in his opening speech during the national workshop on the Rural Development Strategic Framework, held on 18-19 November 2013 at the nation’s capital of Nay Pyi Taw.

President U Thein Sein’s message centered on the political, social, and economic reforms that must take place to bring political stability and lasting peace, and less incidence of poverty. He said that food security, rural development, poverty reduction, and a sustainable economy must develop parallel with the economic, social, health, and education sectors after peace and stability are restored.

The president also cited the important role of the international scientific community in providing technologies that will help ensure sustainable food production and preserve the country’s natural resources at the same time. “Myanmar has to exert utmost effort in the task of reducing the poverty rate from 26% to 16% by 2015.”

The IRRI Myanmar office put up an exhibit alongside the workshop that featured samples of new stress-tolerant high-yielding rice varieties selected during participatory varietal selection activities held in the Delta; and publications, videos, and posters depicting IRRI’s activities in Myanmar.

Madonna Casimero, IRRI representative for Myanmar, and May Nwe Soe, assistant scientist, were participants in the workshop, which was organized by the Ministry of Livestock, Fisheries, and Rural Development and the Livelihood and Food Security Trust.

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Thailand: Preparations under way for rice congress in 2014

The International Rice Congress (IRC2014) is where the world’s rice scientists will gather to share their recent findings in all research areas that have to do with rice. The congress will be held in October 2014 at the Bangkok International Trade and Exhibition Centre (BITEC).

The schedule has been set for the conference and arrangements are being made for plenary and special symposia speakers. Mike Jackson, chair of the science program for IRC2014, is at IRRI for two weeks to meet with the science committee for the conference and with coordinators of the symposia. He is also already deep in planning program details with conference organizers in Bangkok.

Details and updates will be posted on the conference website as well as on Facebook and the IRC2014 blog.

Website: http://ricecongress.com/main/
Facebook: https://www.facebook.com/ScienceAtThe4thInternationalRiceCongress2014
Blog: http://irc2014science.wordpress.com/

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Philippines: Yolanda fund drive continues

Sylvia Avance of the IRRI Partnerships Office
turned over donations from staff to
the Philippine Red Cross on 21 Nov. 2013

IRRI initial collection of donations from its staff (Yolanda fund drive) for those affected by Typhoon Haiyan (local name Yolanda) were turned over by the Philippine Desk of the Partnerships Office to the Philippine National Red Cross on 21 November 2013.

The Partnerships Office will continue to accept donations from staff until Friday, 29 November 2013.

As part of its response to the disaster, IRRI is working closely with the Philippine Department of Agriculture to determine the extent of typhoon damage on rice production and to provide seeds of flood-tolerant rice to farmers for free.

Related stories | IRRI offers rice seed aid for Leyte farmers,
Post-typhoon rice damage assessed in the Philippines, Yolanda survivors to get help from IRRI

Learn more about IRRI (www.irri.org) or follow us on the social media and networks (all links down the right column).

reade more...

Fonetic Adds Voice Biometrics To Its Award-Winning Dodd-Frank Record Keeping Compliance and Trade Reconstruction Solution

MADRID, Nov. 14, 2013 /PRNewswire/ -- Fonetic today announced it has integrated voice biometrics capabilities into its Dodd-Frank Trading Record Keeping Compliance Solution. Fonetic is the first solution provider to utilize voice biometrics to enhance bank compliance with Dodd-Frank Title VII mandates for accurate voice and data record keeping, and as a means for compliance officers to greatly improve risk and fraud detection and prevention.

Fonetic's solution captures, indexes, analyzes and extracts relevant unstructured data from all voice, email and chat interactions to create a fully-searchable database of all communications pertaining to a bank's traders and trades. By adding biometric voice analysis, Fonetic empowers banks to verify a caller's identity, track their interactions, and authenticate transactions based on their unique voiceprint. With even the smallest voice sample, Fonetic can scan millions of calls and cross-match voiceprints with other known criteria – such as call content – to identify the caller. Once identified, the caller's voice becomes searchable data that banks can use to facilitate regulatory inquiries or quickly identify inappropriate trading behaviors.

"Voice recordings play a critical role in helping banks maintain regulatory compliance and protect themselves against risk and fraud, but they become an infinitely more powerful tool when banks can use them to verify who is actually speaking with whom," said Juan Manuel Soto, CEO, Fonetic. "Fonetic's new biometric voice analysis capability helps banks 'connect the dots' between the speaker and their words, which improves communication transparency and increases protection for the organization."

Soto continues, "For banks looking to implement a Dodd-Frank trading record keeping solution before the April 2014 deadline, Fonetic's solution is still the only fully-functioning and proven platform available on the market, and we continue to drive industry innovation by being the first to integrate biometric voice analysis."

Fonetic's voice biometrics capabilities benefit banks in numerous ways, including:

Trader Identification/Verification: With only a few seconds of conversation, Fonetic can quickly verify a trader's identity. This is very useful to track traders conducting business from phones other than their designated line or traders who try to mask their identity. It can also flag restricted talk among traders or identify who was speaking during conference calls. Counterparty Recognition: Fonetic can help banks identify counterparties with whom their traders frequently speak. This could be used to trace deals from a broker's perspective, such as whether the broker has requested several prices from the bank. It can also be used to set up a black list of brokers and traders with whom the bank does not wish to work, and track them even if they switch to a new financial institution. Trade Reconstruction: Recognizing the same voice or group of voices in different calls simplifies trade reconstruction. Filtering by voiceprint pairs can help banks find pre-deal, deal and post-deal conversations with the same counterparty or broker independent of the financial institution involved. Compliance and Reporting: Identifying and analyzing calls belonging to the same trader and counterparty can be used for statistical reports, such as how long or often traders speak with clients, or to create alerts, such as tracking suspected financial abuse or calls with black-listed traders.Fonetic's award-winning Trading Record Keeping Compliance Solution was developed in 2009 for Banco Bilbao Vizcaya Argentaria (BBVA) to proactively prevent market abuse and adhere to stringent legislation. The solution, also implemented globally by The Santander Group, can monitor communications in up to 79 different languages and dialects, enabling compliance officers to find specific information and reconstruct all interactions associated with a trade in moments.

Fonetic's voice biometrics technology is provided by AGNITIO, the worldwide market leader in voice biometrics solutions for the government and commercial sectors, whose extensive customer base includes police, intelligence, military and other government organizations, as well as banks and financial institutions in more than 35 countries. AGNITIO's sophisticated algorithms allow for more accurate calculations of Likelihood Ratios involved in speaker verification, providing the highest level of accuracy, flexibility, and performance.

About Fonetic
Fonetic helps businesses and institutions get to know and understand their customers better. The company works with major international banks, contact centres and utility companies including Vodafone, Telefonica, Santander, BBVA and Direct Line (Linea Directa). Fonetic brings social media, data analytics, sentiment analysis and unstructured data together into a single multi-channel, multi-language solution that decodes customer behaviour and makes recommendations on how to act. Its Dodd-Frank Record Keeping Compliance Solution is the only linguistic-based solution in the market that enables banks to meet the latest record keeping requirements on derivative and swap trading ahead of the April 2014 compliance deadline.

SOURCE Fonetic

90 Minute DNA Results, A First Of Its Kind, Coming To Bensalem

LORTON, Va., Nov. 19, 2013 /PRNewswire/ -- The Bensalem Township Police Department, in conjunction with Bode Technology, is launching a new initiative in the field of DNA testing. This pilot program known as "BodeHITS - Rapid DNA" will be the first of its kind in the country for law enforcement.

Bensalem Township Police Department currently has its own local DNA database with over 6,000 DNA profiles consisting of evidence and reference/individual samples. Bensalem's local DNA database has been in existence since 2010 and DNA testing and analysis has played a role in over 100 criminal investigations. Many of these cases with DNA evidence were property crimes where DNA testing was traditionally not feasible.

Having a local database has guaranteed DNA analysis and results within a 30 day period. This turnaround time has led to the ability to investigate crimes much more efficiently, rather than waiting the six to nine months it would take to previously obtain DNA results. Bode Technology is located in Lorton, VA and currently maintains and analyzes all of Bensalem's DNA profiles.

The BodeHITS-Rapid DNA™ initiative will take DNA testing to the next level. This program will provide Bensalem Police the ability to have real time results with their DNA samples. The turnaround time for DNA results under this program is 90 minutes. The Rapid DNA testing implemented by Bode and enabled by Life Technologies products and services is the first of their kind in the field - in that it can test DNA evidence from a crime scene. Currently, there are several other police departments in the country evaluating rapid DNA instruments; however, those instruments are only validated for single source reference/individual samples. Additionally, those instruments only have the ability to test five samples per batch, whereas with BodeHITS - Rapid DNA, the capacity is 18 samples per batch. This rapid program is also comparing all new DNA profiles to the already existing 6,000 DNA profiles in Bensalem's local database. The goal is to generate near, real-time DNA matches to generate probable cause arrests from active criminals in active investigations.

The BodeHITS - Rapid DNA program with Bensalem is taking place at Bensalem Township Police headquarters. Bode Technology provided the services and a forensic scientist; Life Technologies, the market leader in DNA testing systems, provided 3500xL Genetic Analyzer, AmpFLSTR® Identifiler® PCR Amplification Kits and ongoing support required to perform DNA testing. Bode is also offering reach back support to review DNA HITS.

"From the streets to results in 90 minutes"

About The Bode Technology Group, Inc.

Bode operates one of the most internationally respected private DNA laboratories and provides a comprehensive set of state-of-the-art forensic DNA collection products, analysis services, and research services to law enforcement, justice system, and other government agencies around the world. Bode is one of the three wholly owned subsidiaries of SolutionPoint International, Inc.

SOURCE The Bode Technology Group, Inc.

Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation

Wake Forest Baptist Medical Center Logo. (PRNewsFoto/Wake Forest Baptist Medical Center)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";WINSTON-SALEM, N.C., Nov. 14, 2013 /PRNewswire/ -- Wake Forest Baptist Medical Center today announced that it has entered into a first-of-its-kind strategic affiliation agreement in the Triad with Cornerstone Health Care, P.A. through its wholly-owned management services organization Cornerstone Health Enablement Strategic Solutions, LLC (CHESS).

The goal of the affiliation is to better position both partners for new models of health care delivery driven by health care reform. Both organizations describe the future as one that will emphasize value health care delivery and population management across diseases, such as managing large populations of patients with diabetes or heart failure using a variety of innovative technologies. These future models could allow patients to access support services such as case management, home-based care, weight management and a variety of customized services to support groups of patients with specific diseases or shared characteristics.

The affiliation supports Wake Forest Baptist's mission to improve health throughout the region. John D. McConnell, M.D., chief executive officer of Wake Forest Baptist Medical Center, called the agreement a strategic partnership whose time had come and was driven by a shared vision of patient-centered care that goes beyond the normal boundaries of a hospital or doctor's office. "It is crucial in this challenging health care environment for multiple health care providers to join together and assume accountability for managing and improving health care," McConnell said. "Through better care coordination, we plan to provide more integrated care with fewer duplicated services, increased patient access to support services, and lower total health care costs."

Grace Terrell, M.D., chief executive officer for Cornerstone Health Care, said, "This is the first-of-its-kind Triad partnership between an academic medical center and an independent, multi-specialty provider group. Our joint goal is to enhance the quality of patient care while decreasing overall health care costs by leveraging each organization's strengths to accomplish these objectives."

By partnering through CHESS, Wake Forest Baptist and Cornerstone Health Care immediately expand their capabilities to engage in population management and advanced analytics, with the additional expertise of a world-class research enterprise at Wake Forest Baptist Medical Center. The synergies of these important elements will benefit a much larger group of patients, as well as create a highly-sophisticated accountable care organization (ACO) that will include high-performance networks (HPNs), clinical integration, research, innovative IT applications, support services and case management.

More information regarding the specifics of the affiliation will be provided as available.

Wake Forest Baptist Medical Center (wakehealth.edu) is a fully integrated academic medical center located in Winston-Salem, N.C. The institution comprises Wake Forest School of Medicine, a leading center for medical education and research; Wake Forest Baptist Health, the integrated clinical structure that includes nationally ranked Brenner Children's Hospital; Wake Forest Innovations, which promotes the commercialization of research discoveries and operates Wake Forest Innovation Quarter, an urban research and technology park; plus a network of affiliated community hospitals, physician practices, outpatient services and other medical facilities. Wake Forest Baptist clinical programs and the School of Medicine are regularly ranked among the best in the country by U.S. News & World Report.

About Cornerstone Health Care Cornerstone Health Care is a group of more than 370 physicians and mid-level health professionals representing a wide range of specialties. One of the fastest growing physician groups in the Southeast, Cornerstone is a physician-owned and led multi-disciplinary practice with over 90 locations in communities throughout central North Carolina. Recognized as a 2012 Success Story Award® winner for patient satisfaction by Press Ganey Associates, Inc., Cornerstone is transitioning from the traditional "fee-for-service" model to a patient-centered medical home system providing expanded access, increased coordination of care, enhanced patient education for prevention and treatment of chronic disease, and sophisticated technological support. For more information, visit www.cornerstonehealth.com. Follow Cornerstone on Twitter @CornerstoneHCNC.

Image with caption: "Wake Forest Baptist Medical Center Logo". Image available at: http://photos.prnewswire.com/prnh/20131114/MM17440LOGO-a

Image with caption: "Cornerstone Health Care Logo". Image available at: http://photos.prnewswire.com/prnh/20131114/MM17440LOGO-b

SOURCE Wake Forest Baptist Medical Center

Bruin Biometrics, LLC Awarded CE Mark for the SEM Scanner, an Innovative Diagnostic Tool to Detect Pressure Induced Tissue Damage

BBI Logo. (PRNewsFoto/Bruin Biometrics, LLC)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";LOS ANGELES, Nov. 13, 2013 /PRNewswire/ -- Bruin Biometrics, LLC ("BBI") announced today that it has received CE Marking (Conformite Europeenne) in the European Union to market the SEM Scanner. The SEM Scanner is a Class IIA medical device that is intended to detect localized tissue edema and pressure induced tissue damage that may lead to the formation of pressure ulcers (also known as pressure sores, or decubitus ulcers) before damage becomes visible on the skin's surface.

(Logo: http://photos.prnewswire.com/prnh/20131018/LA00429LOGO)

The hand-held, portable SEM Scanner is a point of care diagnostic tool that measures increased fluid content within the skin and underlying tissue known as subepidermal moisture (SEM). SEM can serve as a biophysical marker of inflammation indicative of impending skin damage and pressure ulcer formation. In clinical studies, SEM has been shown to identify pressure-induced tissue damage — including pressure ulcers — up to 10 days before damage becomes visible on the skin's surface.

Early detection of pressure ulcers with the SEM Scanner can lead to targeted interventions, reduced ulceration severity, and early recovery, as well as decreased hospital days. Additional advantages of the SEM Scanner over other diagnostic modalities include objective, evidence-based measurements; non-invasive, rapid results; clear risk assessment documentation; standardized patient assessment; and minimal technical skills for operation.

BBI developed the SEM Scanner in conjunction with research colleagues at the University of California at Los Angeles (UCLA), notably Barbara Bates-Jensen, PhD, RN, CWOCN, FAAN. Bates-Jensen serves as Chair of the Faculty Executive Committee at the UCLA School of Nursing and Associate Adjunct Professor, Medicine at the UCLA David Geffen School of Medicine.

BBI will officially launch the SEM Scanner at the upcoming MEDICA conference taking place in Dusseldorf, Germany, November 20-23, 2013. For additional information, please visit www.bruinbiometrics.com.

SOURCE Bruin Biometrics, LLC

RELATED LINKS
http://www.bruinbiometrics.com

reade more...

Dynasil's RMD Subsidiary Awarded $4 Million in Technology Development Grants by U.S. Department of Energy

WATERTOWN, Mass., Nov. 19, 2013 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL) today announced that its contract research subsidiary, RMD Inc., has received four grants totaling $4.0 million under the U.S. Department of Energy's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs.

"RMD's world-class research in nuclear detection continues to be on the cutting edge of new technologies," said Peter Sulick, Dynasil's Chairman of the Board, Chief Executive Officer and President. "Advanced nuclear detection materials are being developed for the Department of Energy to further replace helium-3 in the critical areas of homeland security and nuclear fuel accountability."

"From accounting for the country's nuclear fuel supply to monitoring the 15 million shipping containers that enter the U.S.'s ports every year for illicit nuclear materials, the new Phase II research projects RMD is undertaking through these SBIR/STTR Programs exemplify some of the world's most demanding security and safety needs," said Kanai Shah, Ph. D. President of Dynasil's RMD subsidiary. "Dynasil is proud to partner with the Department of Energy on these initiatives."

"These Phase II grants capitalize on our technical and scientific capability in the development of scintillation materials and solid state sensors for nuclear detection," Kanai Shah said. "Our work has significant application in the prevention of terrorist attacks and the safe guarding of nuclear materials, as well as in commercial endeavors such as energy exploration, nuclear power plant safety, medical imaging, basic science research and non-destructive testing."

About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets including medical imaging and sensors for non-destructive testing. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents. The Company is based in Watertown, Massachusetts, with additional operations in MA, MN, NY, NJ and the United Kingdom. More information about the Company is available at www.dynasil.com.

Safe Harbor
This news release may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management. These forward-looking statements may be identified by the use of words such as "plans", "intends," "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words. The actual results of the future events described in such forward looking statements could differ materially from those stated in such forward looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to develop and commercialize our products, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's 2012 Annual Report on Form 10 K, as amended on February 14, 2013, including the risk factors contained in Item 1a, the Company's Quarterly Reports on Form 10-Q filed on February 13, 2013, May 15, 2013 and August 12, 2013 and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: (617) 668-6855
pkehe@dynasil.com

SOURCE Dynasil Corporation of America

Suivez vos enfants et vos animaux domestiques grâce à TRAX, le nouveau traceur GPS intelligent

STOCKHOLM, November 26, 2013 /PRNewswire/ --

?L'appareil et son application permettent un suivi en intérieur et en extérieur dans plus de 30 pays

Wonder Technology Solutions (WTS), une jeune entreprise technologique basée en Suède, vient de lancer Trax, un traceur GPS pour enfants et animaux domestiques. Brillants et novateurs, cet appareil intelligent et son application permettent aux utilisateurs de localiser leurs enfants et leurs animaux domestiques à tout moment et depuis n'importe quel endroit. Trax combine un GPS de pointe et une technologie de fusion de capteurs, afin d'offrir des capacités de navigation en intérieur, ainsi qu'un suivi en extérieur plus précis et en temps réel.

(Logo: http://photos.prnewswire.com/prnh/20131022/648023 )

Conçu pour les smartphones, les appareils mobiles et les ordinateurs, Trax permet aux parents et aux propriétaires d'animaux domestiques de rester en contact avec leurs êtres chers, dans des endroits tels que des terrains de jeux, des centres commerciaux, des écoles, des parcs d'attractions, des sentiers de randonnée et pratiquement n'importe quel autre endroit. Le système Trax est équipé d'un étui en silicone durable et étanche qui résiste aux chutes, à l'eau, à la boue, à la neige et à d'autres contraintes environnementales. Il inclut également une technologie intelligente qui envoie des alertes push lorsqu'un enfant ou un animal quitte une zone définie, lorsque la batterie est faible ou lorsque l'appareil tombe ou dépasse une vitesse prédéterminée.

« Nous avons développé le traceur GPS Trax car les parents et les propriétaires d'animaux domestiques ont besoin d'un appareil plus petit et facile à utiliser, afin de rester à proximité de leurs êtres chers. Le développement du système de navigation en intérieur rend Trax particulièrement unique et utile », a déclaré Fredrik Danelius, cofondateur et PDG de WTS.

L'application

Le traceur GPS Trax peut être localisé à l'aide d'une application gratuite qui propose un suivi en temps réel, une prise en charge des zones sécurisées et des fonctionnalités de réalité augmentée. L'application permet également de définir un nombre illimité de zones sécurisées en fonction de l'heure. Par exemple, une zone sécurisée peut être activée pendant qu'un enfant est à l'école, tandis qu'une zone différente le sera quand ce même enfant se trouvera dans un parc. L'application permet également à d'autres personnes d'accéder au traceur GPS Trax pendant une période spécifique, par exemple pendant qu'un chien se promène avec quelqu'un ou qu'un enfant est en compagnie de sa nourrice.

Tarifs et disponibilité

WTS a conclu un partenariat avec Telenor Connexion pour distribuer le traceur GPS Trax dans plus de 30 pays en 2013, notamment au Royaume-Uni, en France, en Allemagne, en Espagne, au Benelux et dans les pays nordiques. Le système Trax sera lancé dans d'autres pays en 2014. Trax est disponible au tarif de 199 €, ce qui comprend deux années de transmission de données et d'itinérance gratuites dans plus de 30 pays. Les clients effectuant leur achat sur Internet depuis certains pays européens peuvent également opter pour une formule d'abonnement d'un montant mensuel de 6,49 € pour deux ans, sans frais initiaux.

Les traceurs GPS Trax seront disponibles en décembre et l'application Trax sera téléchargeable sur l'App Store et sur Google Play. Les applications pour Windows Phone et pour les tablettes sont en cours développement.

A propos de WTS

Fondée en 2012, WTS - Wonder Technology Solutions est une jeune entreprise basée à Stockholm. WTS a pour objectif d'améliorer l'existence en proposant des produits et des services fiables, amusants, intuitifs et intelligents. WTS cherche à révolutionner les services basés sur la localisation en employant des technologies intelligentes et des conceptions innovantes. Son premier produit, le traceur GPS Trax pour enfants et animaux domestiques, sera disponible dans le monde entier en 2013. Pour tout complément d'information, veuillez consulter le site http://www.TraxFamily.com.

Contact auprès des médias
Tina Hammar
tina.hammar@traxFamily.com
+46-707-41-70-72

Maria Bustamante
maria.bustamante@trax4you.com
+46-73-200-0151

SOURCE WTS – Wonder Technology Solutions

reade more...

RatingDietPlans.com Has Created The Ultimate List of Holiday Dieting Tips

RatingDietPlans.com Has Created The Ultimate List of Holiday Dieting Tips. (PRNewsFoto/RatingDietPlans.com)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";TAMPA, Fla., Nov. 20, 2013 /PRNewswire-iReach/ -- www.RatingDietPlans.com, a website designed to help people find their perfect diet plan, has released a November feature titled "26 Holiday Dieting Tips That Will Keep You Food Coma Free!"

(Photo: http://photos.prnewswire.com/prnh/20131120/MN20818)

While many think of the holiday season as "the most wonderful time of the year", there are also those that absolutely dread this time. For those that are watching their waistlines and trying to lose weight, the holiday season can be some of the most stressful times because of the never-ending temptations that creep up at each and every holiday event they attend. Even simple shopping trips and family gatherings can lead to overeating because, during the hustle and bustle of the holiday season, most tend to throw their weight loss goals out the window and figure they can start over come New Year's Day. This mentality has led to the average American's waistline slowly increasing each year with an average holiday weight gain of one to three pounds during the last two months of the year alone.

Luckily, there is help for those that want to avoid excess holiday weight gain thanks to a detailed and comprehensive list of tips and tricks to help you steer clear of holiday temptation. The authors responsible for many of the hit websites by Advertising Commissions LLC have brought you the ultimate list of holiday dieting tips, and it could not have come at a better time considering the first of many holiday feasts, Thanksgiving, is right around the corner. The list dieting tips brings you 26 of the most helpful ways to avoid temptation, and focus on the people at the gatherings instead of the food. The article gives dieters useful advice that they can implement immediately. and handle this holiday season differently than they have in years past. With the tips and tricks provided, dieters can not only avoid gaining weight, they can also use the tips to shed a few pounds during the holiday season and afterwards as well. Many of the tips can be carried into the rest of the year, and implemented when attending functions such as weddings, birthday parties and other special occasions.

Holiday weight gain statistics have shown repeatedly that weight gained during the holiday season is typically never lost again, and it can increase yearly, adding one to three pounds annually. A study of almost 200 adults conducted by The New England Journal of Medicine in 2000 proved this, and for those that are already overweight, the weight gain can be even more severe. While those that are average weight only gain one to three pounds during the holiday season, those that enter this time of year already overweight gain five pounds or more during this time period. Over time, such weight gain can be detrimental to someone's health and something will have to be done to change the situation.

From planning ahead by bringing healthy snacks to taking the two-bite approach and scanning the room prior to raiding the buffet table, this holiday dieting guide will provide you with a handy list of suggestions you can use to avoid falling victim to the dreaded holiday pounds. Check it out here .

Media Contact: Julian Hooks, RatingDietPlans.com, (813) 445-3837, julian@advertising-commissions.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RatingDietPlans.com

RELATED LINKS
http://www.ratingdietplans.com

reade more...

Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A

DEERFIELD, Ill., Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile.

BAX 855 was designed based on the full-length ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] molecule, a product with 10 years of real-world experience. The BAX 855 molecule was modified with PEGylation technology designed to extend its duration of activity in the body.

"The BAX 855 development program is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with hemophilia," said Anders Ullman, M.D., Ph.D., vice president of global research and development in Baxter's BioScience business. "We are focused first and foremost on strategies to address optimal efficacy and minimize patients' bleeding episodes, while at the same time delivering on the convenience of less frequent dosing for this population with severe disease."

The Phase II/III multi-center, open-label study called PROLONG-ATE is evaluating BAX 855 among 146 adult patients with previously-treated severe hemophilia A. Patients participating in PROLONG-ATE receive treatment twice weekly (45 IU/kg) and are followed for six months. The primary endpoint of the study is the annualized bleed rate (ABR) during the treatment period. The study is also evaluating the safety and immunogenicity of the compound when administered on either prophylaxis and on-demand treatment regimens. Other outcome measures include number of infusions needed to treat bleeding episodes, time intervals between these episodes, pharmacokinetics and patient reported outcomes. To date, no inhibitors or safety issues have been reported in the study.

Based upon the results of the study, the company expects to complete the trial and file for regulatory approval late in 2014. Baxter is also initiating a continuation study for all patients who complete the pivotal Phase II/III study, and expects to initiate a study of BAX 855 among pediatric patients in 2014.

The treatment protocol is based on the results of a Phase I trial of BAX 855, assessing its safety, tolerability and pharmacokinetics. That trial found that the half-life (measuring the duration of activity of the drug in the body) of the investigational compound was approximately 1.5-fold higher compared to ADVATE. An extended half-life was achieved in all patients in the study using BAX 855, no patients developed inhibitors to either the base molecule, BAX 855 or to PEG, and no patients had allergic reactions. No treatment-related or serious adverse events were reported, and no patients withdrew from the study due to adverse events.

BAX 855 is built from the same native FVIII protein used in the production of ADVATE, and employs proprietary PEGylation technology from Nektar Therapeutics (NASDAQ: NKTR) designed to extend the duration of activity of proteins. PEGylation technology has been widely used in various approved treatments.

About ADVATE

ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] is indicated for the control and prevention of bleeding episodes in adults and children (0-16 years) with hemophilia A. ADVATE is also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children (0-16 years) with hemophilia A. ADVATE is not indicated for the treatment of von Willebrand disease.

ADVATE has a demonstrated efficacy profile and a low rate of inhibitor development. ADVATE is a full-length (derived from the complete FVIII gene) recombinant FVIII product that is processed without any blood-based additives. Because no blood-derived components are added at any stage of the manufacturing process, the potential risk of transmitting pathogens that may be carried in blood-based additives is eliminated. There have been no confirmed reports of transmission of HIV, HBV or HCV with rFVIII treatments.

ADVATE is approved in 60 countries worldwide including the United States, Canada, 27 countries in the European Union, Argentina, Australia, Brazil, Chile, China, Colombia, Croatia, Ecuador, Hong Kong, Iceland, Iraq, Japan, Kuwait, Macau, Malaysia, Mexico, New Zealand, Norway, Panama, Puerto Rico, Serbia, Singapore, South Korea, Suriname, Switzerland, Taiwan, Tunisia, Turkey, Ukraine, Uruguay, and Venezuela.

Detailed Important Risk Information for ADVATE

ADVATE is contraindicated in patients with known anaphylaxis to mouse or hamster protein or other constituents of the product.

Allergic-type hypersensitivity reactions, including anaphylaxis, are possible and have been reported with ADVATE. Symptoms have manifested as dizziness, paresthesias, rash, flushing, face swelling, urticaria, dyspnea, and pruritus. Discontinue use if hypersensitivity symptoms occur and administer appropriate emergency treatment.

Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests. Inhibitors have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs).

If expected plasma FVIII levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures FVIII inhibitor concentration.

The serious adverse reactions seen with ADVATE are hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to FVIII.

The most common adverse reactions observed in clinical trials (frequency greater than or equal to 10 percent of subjects) were pyrexia, headache, cough, nasopharyngitis, vomiting, arthralgia, and limb injury.

Please see full prescribing information for ADVATE at: http://www.baxter.com/downloads/healthcare_professionals/products/ADVATE_PI.pdf

About Hemophilia A

Hemophilia is a rare genetic[1] blood clotting disorder and the most severe forms of the disease primarily affect males.[2] People living with hemophilia do not have enough of, or are missing, one of the blood clotting proteins naturally found in blood.[3] Two of the most common forms of hemophilia are A and B. In people with hemophilia A, clotting factor VIII is not present in sufficient amounts or is absent. Without enough FVIII, people with hemophilia can experience spontaneous, uncontrolled internal bleeding that is painful, debilitating, damaging to joints and potentially fatal.[4] According to the World Federation of Hemophilia, it is estimated that more than 400,000 people in the world have hemophilia. [5] All races and economic groups are affected equally.[6]

About Baxter in Hemophilia

Baxter has more than 60 years experience in hemophilia and has introduced a number of therapeutic firsts for hemophilia patients. Baxter has the broadest portfolio of hemophilia treatments in the industry and is able to meet individual therapy choices, providing a range of options at each treatment stage. The company's work focuses on optimizing hemophilia care and improving the lives of people worldwide living with bleeding disorders.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning BAX 855 and related clinical studies, including expectations with regard to regulatory filings. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; additional clinical results; changes in laws and regulations; product quality or supply or patient safety issues; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Media Contact
Brian Kyhos
(224) 948-5353, media@baxter.com

Investor Contact
Mary Kay Ladone, (224) 948-3371

[1] How do you get hemophilia? World Federation of Hemophilia. Accessed on: June 3, 2013. Available at: http://www.wfh.org/en/page.aspx?pid=644
[2] Frequently Asked Questions About Hemophilia. World Federation of Hemophilia. Accessed on: June 3, 2013. Available at: http://www.wfh.org/en/page.aspx?pid=637
[3] What is Hemophilia? World Federation of Hemophilia. Accessed on: June 3, 2013. Available at: http://www.wfh.org/en/page.aspx?pid=646
[4] Lee, C. A. Hemophilia Care in the Modern World, in Current and Future Issues in Hemophilia Care (eds E.-C. Rodriguez-Merchan and L. A. Valentino), 2011.
[5] Treatment. World Federation of Hemophilia. Accessed on June 3, 2013. Available at: http://www.wfh.org/en/page.aspx?pid=642
[6] What is Hemophilia? Hemophilia Federation of America. Accessed on June 3, 2013. Available at: http://www.hemophiliafed.org/bleeding-disorders/hemophilia/

SOURCE Nektar Therapeutics

Inovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award

Inovio Pharmaceuticals, Inc. (PRNewsFoto/Inovio Pharmaceuticals, Inc.)jwplayer.key="2kY/GKwZ2uQZmDlQ9VYArfZt2b4+KhHX3+DM4zisgtE=";BLUE BELL, Pa., Nov. 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its President & CEO, Dr. J. Joseph Kim, has been selected to receive the 2013 Achievement in Drug Discovery and Development Award from the Korean American Society in Biotech and Pharmaceuticals ("KASBP"). The Society aims to contribute to the growth of drug discovery and development through collaborations and information exchanges between U.S. and Korean pharmaceutical companies and research centers.

The award, sponsored by Daewoong Pharmaceuticals Inc., the leading Korean pharmaceutical company, recognizes Dr. Kim as one of the leaders in moving the field of DNA vaccines from theory to application and development. Dr. Kim founded VGX Pharmaceuticals, which through acquisition became Inovio, and is the leading biotech company advancing DNA vaccines toward commercialization. Inovio is revolutionizing vaccines and immunotherapies to prevent and treat cancers and challenging infectious diseases with products in Phase II development.

Jae-Hun Kim, Ph.D. of Merck Research Laboratories, the current KASBP President, said, "We are very pleased to present the award to Dr. Joseph Kim. The award committee recognized Dr. Kim's significant achievement for invention and development of the technology as a scientist and as a businessman."

Dr. J. Joseph Kim, President & CEO of Inovio Pharmaceuticals said, "This honor recognizes the work of countless scientists who, like me, have pursued the potential of DNA vaccines because we understand the paradigm-changing contribution that DNA vaccines will make to human health. At Inovio, we've shown clinical results that no other organization can match in generating T cells. We believe this technology will change the practice of medicine in treating cancer, HIV, hepatitis, malaria and other infectious diseases. I thank KASBP for this award and for their tireless work in building a bridge between the U.S. and Korea with a goal to advance drug discovery and development."

About the Korean American Society in Biotech and Pharmaceuticals ("KASBP")

The Korean American Society in Biotech and Pharmaceuticals ("KASBP") is a non-profit organization founded in May 2001. The current members include Korean-American professionals working throughout the U.S., mostly in the Biotech or Pharmaceutical field. The member profile includes not only professionals working in 100 pharmaceutical industries (BMS, Novartis, GSK, Merck, Sanofi, J&J, Pfizer, etc.), but also scientists in academics serving universities as faculty members, researchers, post-docs, or graduate students; as well as government employees in the FDA, NIH, and other local and federal government organizations.

KASBP aims to promote scientific recognitions in the community, especially for drug discovery and development. KASBP's activities include annual symposiums to contribute to the advancement of drug discovery, development and other pharmaceutical technology in Korean and U.S. companies. Through a collaboration and networking among the members in Biotech companies, pharmaceutical companies and government funded research centers; KASBP has been helping new drug discovery, technology transfer, drug development and commercialization by Korean companies in Korea and in the U.S markets. One important goal of KASBP is to identify and nurture young Korean-American researchers to become future leaders for Biotech and Pharmaceutical industries in Korea and the U.S. by awarding scholarships.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended September 30, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

SOURCE Inovio Pharmaceuticals, Inc.

Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated initial progress in its research collaboration with Biogen Idec, M.A. ("Biogen Idec") to discover microRNAs as biomarkers for multiple sclerosis ("MS") and has received a milestone payment.

Regulus has developed a highly reproducible, proprietary platform for extracting, profiling, and analyzing microRNAs from small volumes of serum. Under its collaboration with Biogen Idec, Regulus applied this platform to profile over 400 serum samples from MS patients and compared these samples against those from healthy volunteers in the largest known MS serum profiling experiment performed to date. The results of this large and successful experiment have provided the foundation for identifying potential biomarker signatures for patients with MS. Based on the initial progress, Regulus and Biogen Idec will now work on the next phase of the research collaboration to validate further the microRNA biomarker signatures in patients with relapse-remitting MS, the most common form of the disease.

"We are very excited about our early success in this collaboration and are hopeful that our efforts advance Biogen Idec's work in treating MS," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "Further, we believe that achievement of this milestone assigns significant value to our proprietary technology and demonstrates the potential of our emerging biomarkers platform to support our microRNA therapeutic pipeline." Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.

In August 2012, Regulus entered into a research collaboration with Biogen Idec to explore microRNAs as biomarkers for disease monitoring and response to therapy. In June 2013, Regulus and Biogen Idec amended the collaboration agreement to update the research plan and criteria for success. The collaboration is initially focused on the discovery of microRNAs as biomarkers for MS. Under the transaction, Regulus has received an upfront payment and has earned an initial milestone payment and is also eligible to receive additional milestone payments. Additionally, Biogen Idec made an investment in Regulus in the form of a promissory note that converted into shares of Regulus' common stock upon the closing of the Company's initial public offering in October 2012.

About microRNAs and microRNAs as Biomarkers

The discovery of microRNAs in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 500 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. microRNA expression, or function, has been shown to be significantly altered or dysregulated in many disease states, including oncology, fibrosis and metabolic diseases. Regulus believes that microRNAs are clinically relevant therapeutic targets and may be ideally suited as biomarkers for these disease states and others, like MS.

microRNAs have been detected in bodily fluids such as blood, and emerging data has demonstrated that microRNA signatures in blood can mimic the expression profile observed in disease tissues. Regulus has a comprehensive intellectual property estate and oligonucleotide technology know-how and believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company. Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection. Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi. In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging microRNA biomarkers platform.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Pages

.